Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31387757 | 1.00 | HPGD (0.42) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL320729 | 0.91 | USP2 (0.44) | HPGDUSP2SMN1; SMN2NR1H2RORC | |
| SCHEMBL29719128 | 0.91 | USP2 (0.44) | HPGDUSP2SMN1; SMN2NR1H2RORC | |
| SCHEMBL19637316 | 0.91 | USP2 (0.44) | HPGDUSP2SMN1; SMN2NR1H2RORC | |
| SCHEMBL21664406 | 0.88 | HPGD (0.42) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL12179888 | 0.88 | HPGD (0.42) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL26667346 | 0.88 | HPGD (0.46) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL2897254 | 0.87 | HPGD (0.41) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL28914034 | 0.87 | HPGD (0.41) | HPGDUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL17386554 | 0.86 | HPGD (0.43) | HPGDUSP2SMN1; SMN2NR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-118525018-A | Bialkyne compound and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-09-28 | — | — | US | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006056873-A2 | THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-06-01 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | HPGD 4099/4885USP2 2094/4885SMN1; SMN2 218/4885 |
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | HPGD 2164/4885USP2 2868/4885SMN1; SMN2 206/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | HPGD 2822/4885USP2 4/4885SMN1; SMN2 2350/4885 |
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | HPGD 1115/4885USP2 3458/4885SMN1; SMN2 4372/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | HPGD 224/4885USP2 4128/4885SMN1; SMN2 3547/4885 |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | P2RX3, P2RX4, ACHE | HPGD 1782/4885USP2 3597/4885SMN1; SMN2 314/4885 |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | P2RX3, P2RX4, ACHE | HPGD 1782/4885USP2 3597/4885SMN1; SMN2 314/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | HPGD 4394/4885USP2 3743/4885SMN1; SMN2 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.